Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2287]

OncoAlert and ecancer - ESMO 2021 Day 5

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer - ESMO 2021 Day 5 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity

Dr Danny Nguyen - City of Hope, Orange County, USA

Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity ( Dr Danny Nguyen - City of Hope, Orange County, USA )

PARP inhibitors in prostate cancer: Case based testing and clinical decisions

Dr Neal Shore and Prof Fred Saad

PARP inhibitors in prostate cancer: Case based testing and clinical decisions ( Dr Neal Shore and Prof Fred Saad )

KRYSTAL-1: Adagrasib as monotherapy or combined with cetuximab in patients with...

Dr Jared Weiss - UNC School of Medicine, Chapel Hill, USA

KRYSTAL-1: Adagrasib as monotherapy or combined with cetuximab in patients with CRC harboring a KRASG12C mutation ( Dr Jared Weiss - UNC School of Medicine, Chapel Hill, USA )

Giredestrant plus palbociclib vs anastrozole plus palbociclib for post...

Dr Sara Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA

Giredestrant plus palbociclib vs anastrozole plus palbociclib for post-menopausal, HER2-negative, untreated early breast cancer ( Dr Sara Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )

Novel therapies in multiple myeloma

Dr Joseph Mikhael - Translational Genomics Research Institute, Pheonix, USA

Novel therapies in multiple myeloma ( Dr Joseph Mikhael - Translational Genomics Research Institute, Pheonix, USA )

Abiraterone acetate plus prednisolone added to ADT + docetaxel, gives 25%...

Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France

Abiraterone acetate plus prednisolone added to ADT + docetaxel, gives 25% reduction in risk of death compared to ADT + docetaxel alone in prostate cancer ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )

STAR: First-line sunitinib or pazopanib for locally advanced and/or metastatic...

Prof Janet Brown - University of Sheffield, Sheffield, United Kingdom

STAR: First-line sunitinib or pazopanib for locally advanced and/or metastatic renal cancer ( Prof Janet Brown - University of Sheffield, Sheffield, United Kingdom )

First-line CDK 4/6 inhibition shows OS benefit for metastatic breast cancer

Prof Gabriel Hortobagyi - The University of Texas MD Anderson Cancer Center...

First-line CDK 4/6 inhibition shows OS benefit for metastatic breast cancer ( Prof Gabriel Hortobagyi - The University of Texas MD Anderson Cancer Center, Houston, Texas )

CARTITUDE-2: Ciltacabtagene autoleucel in patients with progressive multiple...

Prof Adam Cohen - University of Pennsylvania, Philadelphia, USA

CARTITUDE-2: Ciltacabtagene autoleucel in patients with progressive multiple myeloma ( Prof Adam Cohen - University of Pennsylvania, Philadelphia, USA )

Phase II trial: Tamoxifen + taselisib or placebo in patients with hormone...

Dr Mafalda Oliveira - Vall d'Hebron University Hospital, Barcelona, Spain

Phase II trial: Tamoxifen + taselisib or placebo in patients with hormone receptor positive (HR+)/HER2- metastatic breast cancer ( Dr Mafalda Oliveira - Vall d'Hebron University Hospital, Barcelona, Spain )

B-cell maturation antigen targeted CD3-engaging bispecific molecule for...

Prof Bhagirathbhai Dholaria - Vanderbilt University Medical Center, Nashville...

$B-cell maturation antigen targeted CD3-engaging bispecific molecule for relapsed or refractory multiple myeloma ( Prof Bhagirathbhai Dholaria - Vanderbilt University Medical Center, Nashville, USA )$

More from ecancer